venlafaxine hydrochloride has been researched along with Bone Loss, Osteoclastic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Civitelli, R; Dixon, D; Garfield, LD; Kennedy, JL; Lenze, EJ; Müller, DJ; Mulsant, BH; Reynolds, CF; Teitelbaum, SL; Todorov, AA | 1 |
Civitelli, R; Dixon, D; Doré, P; Garfield, LD; Lenze, EJ; Mulsant, BH; Reynolds, CF; Shea, ML; Teitelbaum, S | 1 |
1 trial(s) available for venlafaxine hydrochloride and Bone Loss, Osteoclastic
Article | Year |
---|---|
Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.
Topics: Aged; Antidepressive Agents, Second-Generation; Biomarkers; Bone Resorption; Collagen Type I; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
1 other study(ies) available for venlafaxine hydrochloride and Bone Loss, Osteoclastic
Article | Year |
---|---|
Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults.
Topics: Aged; Bone Resorption; Cyclohexanols; Depressive Disorder, Major; Female; Genetic Variation; Humans; Male; Middle Aged; Osteogenesis; Receptor, Serotonin, 5-HT1B; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Venlafaxine Hydrochloride | 2014 |